Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study

Lancet

Volumn 368, Issue 9537, 2006, Pages 744-753

  Rabe, Klaus F ^a   Atienza, Tito ^b   Magyar, Pál ^c   Larsson, Per ^d   Jorup, Carin ^d   Lalloo, Umesh G ^e  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Veterans Memorial Medical Center   (Philippines)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SHORT ACTING DRUG; STEROID; TERBUTALINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; EMERGENCY WARD; FEMALE; HEART PALPITATION; HOSPITALIZATION; HUMAN; LOG RANK TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TACHYCARDIA; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREMOR;

EID: 33747761653     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69284-2     Document Type: Article

References (32)

1. Greening A., Ind P., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344 (1994) 219-224
2. Pauwels R., Lofdahl C.-G., Postma D., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1405-1411
3. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373
4. Wilding P., Clark M., Thompson Coon J., et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 314 (1997) 1441-1446
5. O'Byrne P., Barnes P., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
6. Sin D., Man J., Sharpe H., Gan W., and Man S. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 292 (2004) 367-376
7. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Thorax 58 suppl I (2003) i1-i94
8. Rabe K., Pizzichini E., Ställberg B., et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild to moderate asthma: a randomized, double blind trial. Chest 129 (2006) 246-256
9. O'Byrne P., Bisgaard H., Godard P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
10. Scicchitano R., Aalbers R., Akena D., et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20 (2004) 1403-1418
11. Vogelmeier C., D'Urzo A., Pauwels R., et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 26 (2005) 819-828
12. Seberová E., and Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 94 (2000) 607-611
13. Pauwels R., Sears M., Campbell M., et al., for the RELIEF Study investigators. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 22 (2003) 787-794
14. Tattersfield A., Löfdahl C.-G., Postma D., et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 357 (2001) 257-261
15. American Thoracic Society (ATS). Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136 (1987) 225-244
16. 2-agonist use?. Respir Med 95 (2001) 319-323
17. Suissa S., Ernst P., Boivin J., et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149 (1994) 604-610
18. Bateman E., Boushey H., Bousquet J., Busse W., Clark T., and Pauwels R. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
19. Nelson H., Weiss S., Bleecker E., Yancey S., Dorinsky P., and SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
20. Martinez F. Safety of long-acting beta-agonists-an urgent need to clear the air. N Engl J Med 353 (2005) 2637-2639
21. O'Byrne P., Bisgaard H., Godard P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005). http://ajrccm.atsjournals.org/cgi/data/171/2/129/DC1/1 (accessed Oct 1, 2005)
22. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in paediatric asthma. Chest (in press).
23. Miller-Larsson A., Matsson H., Hjerberg E., Dahlbäck M., Tunek A., and Brattsand R. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 26 (1998) 623-630
24. Toogood J., Baskerville J., Jennings B., et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 70 (1982) 288-298
25. Currie G., Jackson C., Ogston S., and Lipworth B. Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. QJM 96 (2003) 435-440
26. Maneechotesuwan K., Essilfie-Quaye S., Meah S., et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 128 (2005) 1936-1942
27. Wark P., Johnston S., Moric I., Simpson J., Hensley M., and Gibson P. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 19 (2002) 68-75
28. van der Molen T., Partridge M., Myrseth S., and Busse W. Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms. Eur Respir J 26 suppl (2005) 49 (abstr 166)
29. Harrison T., Oborne J., Newton S., et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363 (2004) 271-275
30. FitzGerald J., Becker A., Sears M., Mink S., Chung K., and Lee J. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59 (2004) 550-556
31. Foresi A., Morelli M., and Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 117 (2000) 440-446
32. Angus R., Reagon R., and Cheesbrough A. Short-acting beta2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract 59 (2005) 156-162